会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • 6,9-Nitrilo-prostaglandin analogues
    • 6,9-Nitrilo-prostaglandin类似物
    • US4313954A
    • 1982-02-02
    • US122704
    • 1980-02-19
    • Hirohisa WakatsukaMasaki HayashiYoshitaka Konishi
    • Hirohisa WakatsukaMasaki HayashiYoshitaka Konishi
    • A61K31/557A61P7/02A61P43/00C07C405/00C07D209/52A61K31/40
    • C07C405/0041C07C405/00C07D209/52
    • Prostaglandin I.sub.2 analogues of the general formula ##STR1## [wherein R.sup.1 represents a hydrogen atom, an alkyl group containing from 1 to 12 carbon atoms, an aralkyl group containing from 7 to 13 carbon atoms, a cycloalkyl group containing from 4 to 7 carbon atoms unsubstituted or substituted by at least one alkyl group containing from 1 to 4 carbon atoms, a phenyl group unsubstituted or substituted by at least one halogen atom, trifluoromethyl or phenyl group, or by at least one alkyl, alkoxy or alkylthio group containing from 1 to 4 carbon atoms, or represents a group --C.sub.m H.sub.2m COOR.sup.6, --C.sub.n H.sub.2n OR.sup.7 or ##STR2## in which m represents an integer of 1 to 12, n represents an integer of 2 to 12, R.sup.6, R.sup.8 and R.sup.9, which may be the same or different, each represent an alkyl group containing from 1 to 4 carbon atoms, and R.sup.7 represents a hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms, R.sup.2 represents a hydrogen atom or a methyl or ethyl group, R.sup.3 represents an alkyl group containing from 1 to 4 carbon atoms, R.sup.4 represents a hydrogen atom, or an alkyl group containing from 1 to 4 carbon atoms, R.sup.5 represents an alkyl group containing from 1 to 10 carbon atoms, Y represents ethylene or trans-vinylene, the hydroxy group attached to the C-11 carbon atom is in .alpha.-configuration, and the wavy line attached to the C-15 carbon atom is in .alpha.- or .beta.-configuration or a mixture thereof] and non-toxic acid addition salts thereof and, when R.sup.1 represents a hydrogen atom, non-toxic salts thereof are new compounds possessing pharmacological properties typical of the prostaglandins.
    • 具有通式的前列腺素I2类似物[其中R1表示氢原子,含有1至12个碳原子的烷基,含有7至13个碳原子的芳烷基,含有4至7个碳原子的环烷基 未取代或被至少一个含有1至4个碳原子的烷基取代的苯基,未被取代或被至少一个卤素原子取代的苯基,三氟甲基或苯基,或至少一个含有1至4个碳原子的烷基,烷氧基或烷硫基 4个碳原子,或表示基团-C m H 2 mCOOR 6,-C n H 2n OR 7或其中m表示1至12的整数,n表示2至12的整数,R 6,R 8和R 9可以相同或不同 各自表示含有1至4个碳原子的烷基,R 7表示氢原子或含有1至4个碳原子的烷基,R 2表示氢原子或甲基或乙基,R 3表示含有 从1 至4个碳原子,R 4表示氢原子或含有1至4个碳原子的烷基,R 5表示含有1至10个碳原子的烷基,Y表示亚乙基或反式亚乙烯基, C-11碳原子为α-构型,连接至C-15碳原子的波浪线为α-或β-构型或其混合物)及其无毒的酸加成盐,当R1表示 氢原子,其无毒盐是具有典型的前列腺素的药理学性质的新化合物。
    • 7. 发明申请
    • TEMPERATURE SETTING METHOD OF THERMAL PROCESSING PLATE, COMPUTER-READABLE RECORDING MEDIUM RECORDING PROGRAM THEREON, AND TEMPERATURE SETTING APPARATUS FOR THERMAL PROCESSING PLATE
    • 热处理板的温度设定方法,计算机可读记录介质记录程序及温度设定装置
    • US20080116195A1
    • 2008-05-22
    • US11934303
    • 2007-11-02
    • Megumi JyousakaYoshitaka Konishi
    • Megumi JyousakaYoshitaka Konishi
    • H05B1/02
    • G05D23/1932H01L21/67248
    • In the present invention, a thermal plate of a PEB unit is divided into a plurality of thermal plate regions, and a temperature is settable for each of the thermal plate regions. A temperature correction value for adjusting the temperature within the thermal plate is settable for each of the thermal plate regions of the thermal plate. The line widths within the substrate which has been subjected to the photolithography process are measured, and an improvement in-plane tendency Za improved by change of the temperature settings is subtracted from an in-plane tendency Z of the measured line widths within the substrate to calculate an in-plane tendency Zb of the line widths within the substrate after change of temperature settings. The improvement in-plane tendency Za is calculated using the following expression. Za=−1×α×MT (α: a resist heat sensitivity, M: a calculation model, and T: temperature correction values for thermal plate regions)
    • 在本发明中,将PEB单元的热板分割为多个热板区域,并且可以对每个热板区域设定温度。 用于调节热板内的温度的温度校正值可针对热板的每个热板区域而设定。 测量已进行了光刻处理的基板内的线宽,并从基板内的被测线宽度的面内倾向Z中减去由温度设定的变化而提高的面内倾向Za, 在温度设置更改后,计算衬底内线宽的面内倾向Zb。 使用以下表达式计算平面内倾向Za的改善。 <?in-line-formula description =“In-line Formulas”end =“lead”?> Za = -1xalphaxMT(α:抗蚀剂热敏性,M:计算模型,T:热板区域的温度校正值 )<?in-line-formula description =“In-line Formulas”end =“tail”?>
    • 10. 发明授权
    • Heterocyclic compounds
    • 杂环化合物
    • US6001830A
    • 1999-12-14
    • US189843
    • 1998-11-12
    • Sung Jai LeeYoshitaka KonishiOrest Taras MacinaKigen KondoDingwei Tim YuManton Rodgers FriersonMasafumi Sugitani
    • Sung Jai LeeYoshitaka KonishiOrest Taras MacinaKigen KondoDingwei Tim YuManton Rodgers FriersonMasafumi Sugitani
    • A61K31/505A61P1/16A61P7/02A61P9/00A61P9/08A61P9/10A61P9/12A61P11/00A61P11/08A61P13/02A61P15/00A61P25/28A61P29/00A61P37/04A61P43/00C07D487/04C07D495/04A61K31/50
    • C07D487/04C07D495/04
    • The compounds of the formula: ##STR1## wherein ring ##STR2## is a hetero ring containing nitrogen atom, optionally selected from ##STR3## n is 0-2; Y is bond or alkylene;Z is bond, alkylene or vinylene;E is(i) 4-15 membered, unsaturated, partially saturated or fully saturated, mono or bicyclic hetero ring containing as hetero atoms, 1 or 2 N atoms, 1 or 2 O atoms or 1 S atom,(ii) 4-15 membered, unsaturated or partially saturated, mono or bicyclic carbocyclic ring, or(iii) --OR.sup.4 (in which R.sup.4 is hydrogen atom, alkyl or alkyl substituted by a hydroxy group);Cyc is 5-7 membered, unsaturated, partially saturated or fully saturated, monocyclic hetero ring containing as hetero atoms, 1 or 2 N atoms or 5-7 membered, unsaturated or partially saturated, monocyclic carbocyclic ring;R.sup.1 is H or alkyl;R.sup.2 is H, alkyl, alkoxy or halogen atom;R.sup.3 is H, alkyl, alkoxy or --COOR.sup.5 (in which R.sup.5 is H or alkyl);with the proviso that(1) a Cyc ring should not bond to Z through a nitrogen atom in the Cyc ring when Z is vinylene and that(2) Y is not a single bond, when E is --OR.sup.4 ;or pharmaceutically acceptable acid addition salts thereof, pharmaceutically acceptable salts thereof, or hydrates thereof; have inhibitory effect on cGMP-PDE, or additionally on TXA.sub.2 synthetase.
    • 下式的化合物:其中环是含氮原子的杂环,任选地选自n是0-2; Y是键或亚烷基; Z是键,亚烷基或亚乙烯基; E是(i)含有1或2个N原子,1或2个O原子或1个S原子的4-15元,不饱和,部分饱和或完全饱和的单或双环杂环,(ii)4-15 或(iii)-OR4(其中R4为氢原子,被羟基取代的烷基或烷基);或(iii)-OR4(其中R4为氢原子,被羟基取代的烷基或烷基); 环是含有杂原子,1或2个N原子或5-7元不饱和或部分饱和的单环碳环的5-7元,不饱和,部分饱和或完全饱和的单环杂环; R1是H或烷基; R2是H,烷基,烷氧基或卤素原子; R3是H,烷基,烷氧基或-COOR5(其中R5是H或烷基); 条件是(1)当Z是亚乙烯基时,环环不应通过环中的氮原子与Z键合,并且(2)Y不是单键,当E是-OR4时; 或其药学上可接受的酸加成盐,其药学上可接受的盐或其水合物; 对cGMP-PDE或另外在TXA2合成酶具有抑制作用。